



GW3965

Catalog No: tcsc0842

П	
	Ĺ

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

405911-09-3

Formula:

 $C_{33}H_{31}CIF_3NO_3$

Pathway:

Metabolic Enzyme/Protease

Target:

LXR

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

582.05

Product Description

GW3965 is a potent, selective **LXR** agonist for hLXR α and hLXR β with **EC**₅₀ of 190 and 30 nM, respectively.





IC50 & Target: EC50: 190 nM (hLXR α), 30 nM (hLXR β)

In Vitro: GW3965 promotes GBM cell death in vitro with enhanced efficacy in EGFRvIII-expressing tumor cells. GW3965 up-regulates expression of the cholesterol transporter gene ABCA1 and the E3 ubiquitin ligase IDOL and reduces LDLR levels^[2]. LXR ligands inhibits platelet aggregation and calcium mobilization stimulated by collagen or CRP. GW3965 (1 or 5 μ M) displays a minor inhibitory effect on fibrinogen binding and P-selectin exposure, when platelets are stimulated with 1 μ g/mL CRP. But using higher concentrations of GW3965 (10 μ M) or T0901317 (40 μ M), the levels of fibrinogen and P-selectin on the platelet surface are reduced^[3]

In Vivo: GW3965 induces an increase of neuroactive steroids in the spinal cord, the cerebellum and the cerebral cortex of STZ-rats, but not in the CNS of non-pathological animals. GW3965 treatment induces an increase of dihydroprogesterone in the spinal cord of diabetic animals in association with an increase of myelin basic protein expression^[1]. GW3965 (40 mg/kg, p.o.) strongly induces ABCA1 expression and reduces LDLR expression, and this is accompanied by 59% inhibition of tumor growth, and a 25-fold increase in GBM cell apoptosis in vivo^[2]. GW3965 (2 mg/kg, i.v.) increases bleeding time and modulated platelet thrombus formation in vivo [3].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!